SIGA Technologies (SIGA) Company presentation summary

Strategic positioning and capabilities

• Recognized as a leader in global health security, focusing on infectious diseases and biodefense, with a fully integrated U.S.-based supply chain and deep government contracting experience.

• Operates in over 30 countries, leveraging expertise in infectious disease, health security, and government relations to drive growth and shareholder value.

• Strategic priorities include expanding regulatory approvals, cultivating global partnerships, and moving into complementary therapeutic areas.

• Experienced leadership team with backgrounds in major pharmaceutical and financial organizations.

Product portfolio and innovation

• TPOXX is a foundational antiviral franchise, approved in the U.S., Canada, Europe, UK, and Japan for smallpox and other orthopoxvirus infections.

• Demonstrates strong efficacy and safety, with over 10,000 human subjects in clinical trials and no serious adverse events reported.

• Ongoing development includes pediatric formulations and post-exposure prophylaxis (PEP) label expansion, supported by $27 million in U.S. government funding.

• TPOXX is one of only two approved antivirals for orthopoxvirus treatment, with a differentiated mechanism targeting the VP37 protein.

Market dynamics and threat landscape

• Heightened global awareness of orthopoxvirus threats due to increased risk of natural, accidental, or intentional outbreaks.

• Smallpox remains a significant threat, with most of the global population unvaccinated and vaccines alone insufficient for containment.

• Comprehensive biodefense requires both vaccines and antivirals to safeguard vulnerable populations.